About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Expanding the Preventive Care Frontier: Dr. Reddy’s Launches Sanofi’s Beyfortus® in India

By: AB Newswire

In a significant advancement for infant healthcare in India, Dr. Reddy’s Laboratories (NYSE: RDY) (NSE: DRREDDY) has officially launched Beyfortus® (nirsevimab), a novel preventive treatment for Respiratory Syncytial Virus (RSV) in infants. This launch follows the April 2025 announcement of their expanded partnership with Sanofi Healthcare India Private Limited that granted Dr. Reddy’s exclusive rights to promote and distribute the drug in India.

Addressing an Underreported Health Crisis

According to paediatric experts, RSV causes nearly two-thirds of respiratory infections in infants, yet cases are significantly underreported in India despite being a notifiable disease for decades. A representative of the Indian Academy of Pediatrics, highlighted the severity of the issue, pointing to 2,000+ reported child deaths in 2024 from just Kolkata, Bengaluru, and Mumbai, describing it as merely “the tip of the iceberg.”

Medical experts emphasized at a recent roundtable that almost every child contracts RSV by age two. The virus begins with cold-like symptoms but can rapidly develop into a severe lung infection requiring hospitalization within just three days. While many children recover without complications, doctors noted there’s no reliable way to predict which infants might develop serious conditions such as pneumonia or bronchiolitis.

Strategic Significance in Dr. Reddy’s Growth Portfolio

The Beyfortus® launch represents a key milestone in Dr. Reddy’s dual-track growth strategy, which focuses on both strengthening core businesses and building new value pools through strategic partnerships. According to the company’s FY2025 Integrated Annual Report, vaccines have been a significant driver of Dr. Reddy’s India business growth, which outpaced the Indian Pharmaceutical Market (IPM) at 8.4% versus 8.0% market growth.

Expanding Strategic Partnership Ecosystem

The Beyfortus® distribution agreement builds upon Dr. Reddy’s successful vaccine partnership with Sanofi established in 2024 as part of its strategy of “expanding innovation and building for tomorrow.”

This is part of a broader strategy of high-value collaborations to bring innovation to India that the company has been pursuing, including:

  • A venture with Nestlé India to bring science-backed nutraceuticals to consumers
  • Collaboration with Gilead Sciences to bring HIV drug Lenacapavir to low and lower-middle-income nations
  • A licensing agreement with Takeda to introduce Vonoprazan, a novel acid blocker for treating gastric disorders in India
  • Launch of Toripalimab (Zytorvi), the first immuno-oncology drug approved for nasopharyngeal carcinoma treatment in India
  • Partnership with Bayer for marketing Vericiguat™, expanding Dr. Reddy’s cardiovascular medicine portfolio

 

Enhancing Prevention for a Critical Health Need

As highlighted in the medical roundtable discussions, RSV represents a significant health threat to infants in India, with routine testing and awareness around RSV remaining low despite the scale of the problem. The introduction of Beyfortus® addresses this critical gap in infant healthcare by providing a novel preventive option that can significantly reduce hospitalizations and complications.

With Beyfortus® already approved for use in the European Union, the U.S., China, Japan, and many other countries around the world, its introduction in India represents an important step in aligning the country’s preventive healthcare measures with global standards.

The launch positions Dr. Reddy’s to capitalize on growing awareness of RSV’s impact and increasing demand for preventive treatments in pediatric care. This launch aligns perfectly with the company’s stated philosophy of “Good Health Can’t Wait” and its commitment to addressing unmet patient needs by making expensive medicines affordable and accessible as well as improving disease management.

 

This article was originally published on thefinanceherald.com

 

Recent More from the Finance Herald

Radical Reforms Ahead: Rethinking Federal Reserve Policy to Align with Administration Priorities

Navigating the New Frontier: How Shifting Pentagon Priorities Are Transforming the Aerospace and Defense Landscape

The New Frontier of Health: Privacy, Autonomy, and the Coming Wave of Biometric Surveillance

 

This content is was originally published on The Finance Herald, which is part of the Wall Street Wire Network. The Finance Herald does not guarantee the accuracy, completeness, or timeliness of the information or Services provided. Views and opinions presented through the Services, whether expressed by contributors, columnists, external partners, or employees, are not financial or investment advice, and neither the Wall Street Wire or its operators accept responsibility or liability for any actions, financial or otherwise, taken directly or indirectly as a result of engaging with any of the Services offered. Content produced by or for The Finance Herald may not be reproduced, republished in full, or redistributed in any form without prior written permission from The Finance Herald or the Wall Street Wire Network, as applicable. This content includes paid promotional content brought to you by Wall Street Wire. Wall Street Wire or its operators have received compensation from Dr. Reddy’s Laboratories for distribution and media promotion provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial or investment advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available https://wallstwire.ai/disclosures

Media Contact
Company Name: The Finance Herald
Contact Person: Features Editor
Email: Send Email
Country: United States
Website: https://thefinanceherald.com/

More News

View More
Is Sandisk Still a Buy After 118% AI-Fueled Surge?
Via MarketBeat
Topics Artificial Intelligence
Tickers SNDK
Why GlobalFoundries Just Became a Geopolitical Power Play
Via MarketBeat
Topics Economy World Trade
Tickers GFS
3 Stocks Using Buybacks to Drive Sustainable Price Growth
Via MarketBeat
Tickers AZO ETSY KR
Why These 3 Tech Stocks Deserve Your Attention in Q4
Via MarketBeat
Tickers BRZE LPTH MDB
Is BigBear.ai the Next Palantir?
Via MarketBeat
Topics Artificial Intelligence
Tickers BBAI PLTR
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.